

## Bayer Group Consolidated Statements of Income

€ million

	Note	2002 <sup>1)</sup>	2003
<b>Net sales</b>	[1]	<b>29,624</b>	<b>28,567</b>
<i>of which discontinuing operations</i>	[6]	7,586	6,389
Cost of goods sold		(17,680)	(16,834)
<b>Gross profit</b>		<b>11,944</b>	<b>11,733</b>
Selling expenses	[2]	(6,933)	(6,484)
Research and development expenses	[3]	(2,577)	(2,414)
General administration expenses		(1,460)	(1,690)
Other operating income	[4]	2,706	1,158
Other operating expenses	[5]	(2,070)	(3,506)
<b>Operating result [EBIT]</b>	[7]	<b>1,610</b>	<b>(1,203)</b>
<i>of which discontinuing operations</i>	[6]	760	(1,652)
Income (expense) from investments in affiliated companies – net	[8]	223	(93)
Interest expense – net	[9]	(449)	(353)
Other non-operating expenses – net	[10]	(428)	(345)
<b>Non-operating result</b>		<b>(654)</b>	<b>(791)</b>
<b>Income (loss) before income taxes</b>		<b>956</b>	<b>(1,994)</b>
Income taxes	[11]	107	645
<b>Income (loss) after taxes</b>		<b>1,063</b>	<b>(1,349)</b>
Minority stockholders' interest	[13]	(3)	(12)
<b>Net income (loss)</b>		<b>1,060</b>	<b>(1,361)</b>
<b>Earnings per share (€)</b>	[14]	<b>1.45</b>	<b>(1.86)</b>
<b>Diluted earnings per share (€)</b>	[14]	<b>1.45</b>	<b>(1.86)</b>

<sup>1)</sup> 2002 figures restated